# FDA Grants Accelerated Approval to Tudriqev Plus Nivolumab for Advanced Cutaneous Melanoma

> fda · REPORTED · 2026-08-05

The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed after a PD-1-based regimen. This is a notable regulatory milestone for oncolytic immunotherapy in a difficult-to-treat patient population.

About FDA / Replimune (Tudriqev/vusolimogene oderparepvec): Tudriqev (vusolimogene oderparepvec-wtpg) is an oncolytic immunotherapy developed by Replimune, designed for direct injection into tumors to stimulate an immune response against advanced cutaneous melanoma.

- Company: FDA / Replimune (Tudriqev/vusolimogene oderparepvec)
- Sector: oncology
- Primary source: https://globalrph.com/2026/08/top-20-medical-news-topics-clinicians-should-know-this-week-august-3-9-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.